No Data
Checkpoint Therapeutics Price Target Maintained With a $34.00/Share by HC Wainwright & Co.
Analysts' Top Healthcare Picks: Checkpoint Therapeutics (CKPT), Mediwound (MDWD)
Checkpoint Therapeutics, GC Cell Collaborate on Cancer Research; Shares Rise
Checkpoint, GC Cell to Evaluate Combo Cancer Therapy
Express News | GC Cell And Checkpoint Therapeutics To Explore Combined Therapeutic Potential Of Cosibelimab
Checkpoint Therapeutics (CKPT.US) has submitted its application for the marketing of PD-L1 targeted antibodies to the US FDA.
According to the SmartFinance APP, Checkpoint Therapeutics (CKPT.US) recently announced that it has resubmitted its biological product license application (BLA) for the PD-L1 targeted antibody Cosibelimab to the United States FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) patients who are not suitable for radical surgery or radiotherapy. Data shows that Cosibelimab is a potential differentiated, high-affinity, fully human IgG1 subtype monoclonal antibody that directly binds with PD-L1 to block P.